At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed epithelial ovarian cancer or primary peritoneal carcinoma
- ✓Platinum-resistant disease: progression during or relapse <6 months after most recent platinum-based chemotherapy
- ✓Measurable or evaluable disease (elevated CA-125 ≥100 confirmed on 2 separate occasions ≥2 weeks apart, or imaging-based measurable disease)
- ✓Age ≥18 years
- ✕Prior treatment with gemcitabine or docetaxel
- ✕Peripheral neuropathy grade ≥2
- ✕Underlying medical, psychiatric, or social conditions precluding receipt of treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Gemcitabine for Ovarian Carcinoma and Peritoneal Neoplasms. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is for patients with advanced ovarian cancer that has reappeared after treatment with conventional therapy. The purpose of this study is to determine if the combination of docetaxel and gemcitabine will be effective in reducing or eliminating the tumor(s) in patients with ovarian cancer. Docetaxel is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancer; gemcitabine is approved by the FDA for the treatment of pancreatic and lung cancer. Neither docetaxel nor gemcitabine are approved for the treatment of ovarian cancer. Both drugs have been shown to decrease the size of ovarian cancer tumors.
Study Details
Timeline
Interventions
Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.